Federal Register / Vol. 66, No. 120 / Thursday, June 21, 2001 / Notices 33255

3. Final financial report and

performance report, no later than 90

days after the end of the project period;

and

Note: Send all reports to the Grants

Management Specialist identified in section

‘‘I. Where Can I Get More Information.’’

If funded, CDC staff will visit your

organization to learn about your

activities. When asking for the

continuation awards, you must again

show CDC that you still meet the

requirements stated under ‘‘B. Who Can

Apply?’’.

Note: Successful applicants may be

contacted by the National Prevention

Information Network (NPIN) to obtain

information on their program resources. Your

resources may be used in referrals and

resource directories. If selected for funding,

three copies of all educational materials and

resources developed under this grant should

be sent to NPIN for inclusion in their

databases.

If you develop HIV prevention materials

using CDC funds, you must first check with

NPIN to find out if the same kind of materials

have already been developed.

NPIN also makes available

information and technical assistance

services for use in program planning

and evaluation. They can be contacted

at the numbers and Internet site given

above.

NPIN makes available materials on

HIV, STD, and TB to the general public

through its Internet site

(www.cdcnpin.org), its 1–800 number

(1–800–458–5231; TTY users: 1–800–

243–7012), and fax number (1–888–

282–7681).

Human Subjects Guidelines

If you are conducting a research

project that involves human subjects,

you must ensure that your application

includes or addresses the following:

1. Requirements of Title 45 CFR Part

46 for the protection of human subjects?

(Not scored; however, an application

can be disapproved if the research risks

are sufficiently serious and protection

against risks is so inadequate as to make

the entire application unacceptable.)

2. Requirements of CDC Policy

regarding the inclusion of women,

ethnic, and racial groups in the

proposed research.

This includes:

a. The proposed plan for the inclusion

of both sexes and racial and ethnic

minority populations for appropriate

representation.

b. The proposed justification when

representation is limited or absent.

c. A statement as to whether the

design of the study is adequate to

measure differences when warranted.

d. A statement as to whether the plans

for recruitment and outreach for study

participants include the process of

establishing partnerships with

community(ies) and recognition of

mutual benefits.

Note: Projects that involve the collection of

information from 10 or more individuals and

funded by cooperative agreement will be

subject to review and approval by the Office

of Management and Budget (OMB) under the

Paperwork Reduction Act.

I. Authority and Catalog of Federal

Domestic Assistance Number

This program is authorized under

section 301(a) and 317 of the Public

Health Service Act, [42 U.S.C. section

241(a) and 247(b)], as amended. The

Catalog of Federal Domestic Assistance

number is 93.939.

J. Where To Obtain Additional

Information

CDC strongly suggests that you

supplement this program announcement

as it appears in the Federal Register,

with a copy of the program

announcement that is in an easy-to-use

format. This easy-to-read version can be

found on the CDC home page Internet

address http://www.cdc.gov. Click on

‘‘Funding’’ then ‘‘Grants and

Cooperative Agreements.’’

To request a hard copy of the

application, call 1–888–GRANTS4(1–

888–472–6874). You will be asked to

leave your name and address and will

be instructed to identify the Program

Announcement number you want.

If you have questions after reviewing

the contents of all the documents,

business management technical

assistance may be obtained from: David

A. Wilson, Grants Management

Specialist, Grants Management Branch,

Procurement and Grants Office, Centers

for Disease Control and Prevention,

2920 Brandywine Road, Room 3000,

Atlanta, GA 30341–4146, Telephone

number: 770–488–2700, E-mail address:

DAWilson@cdc.gov.

For program technical assistance,

contact: Bill Comeaux, Project Officer,

Prevention Program Branch, Division of

HIV/AIDS Prevention, Centers for

Disease Control and Prevention, 1600

Clifton Road, NE, MS–E58, Atlanta, GA

30333, Telephone number: 404–639–

0968, E-mail address:

wcomeaux@cdc.gov.

Dated: June 15, 2001.

John L. Williams,

Director, Procurement and Grants Office,

Centers for Disease Control and Prevention

(CDC).

[FR Doc. 01–15595 Filed 6–20–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[Announcement Number 01094]

Professional Education on Prostate

Cancer: Primary Health Care

Providers; Notice of Availability of

Funds; Amendment

A notice announcing the availability

of Fiscal Year 2001 funds to fund a

competing cooperative agreement

program for private and public

nonprofit medical organizations or

associations which was published in the

Federal Register on May 22, 2001 (Vol.

66, No. 99, Pages 28174–28177).

The notice is amended as follows:

On page 28176, Second Column,

under Section F. Submission and

Deadline, the submission due date

should read on or before June 29, 2001.

Dated: June 15, 2001.

Sandra R. Manning,

Acting Director, Procurement and Grants

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 01–15596 Filed 6–20–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Cooperative Research and

Development Agreement (CRADA)

AGENCY: Centers for Disease Control and

Prevention (CDC), HHS.

ACTION: Notice.

SUMMARY: The Centers for Disease

Control and Prevention (CDC) is seeking

a CRADA partner for collaboration to

examine the use of anti-substance P

antibodies and/or anti-substance P

F(ab)′2 antibody fragments to prevent

and/or treat an inflammatory response

mediated by substance P associated

with respiratory viral infection

(particularly respiratory syncytial virus

[RSV]). Anti-substance P antibody

treatment would be used in combination

with agents for anti-viral treatment (e.g.,

Ribavirin, palivizumab, and RSV fusion

inhibitors) to ameliorate substance Pmediated inflammation and disease

pathogenesis.

Because CRADAs are designed to

facilitate the development of scientific

and technologic knowledge into useful,

marketable products, a great deal of

freedom is given to Federal agencies in